Background and Aims EUS-guided portal pressure gradient (EUS-PPG) measurement is a novel method to evaluate hypertension severity. In this study, we determined the consistency between EUS-PPG hepatic venous (HVPG) measurements in patients with acute or subacute hypertension. Methods Twelve were prospectively enrolled. performed using 22-gauge FNA needle central monitor. The HVPG transjugular ap...

Portal hypertension can arise from any condition interfering with normal blood flow at any level within the portal system. Herein, we presented two uncommon cases of the portal hypertension and its treatment with brief literature review. A 71-year-old man who underwent right hemihepatectomy revealed a tumor recurrence adjacent to the inferior vena cava (IVC). After radiofrequency ablation (RFA)...

Proinflammatory (TNF-alpha , IL-1beta, and NO) and antiinflammatory (IL-10, CO) levels were assayed in serum, liver, and small bowel in order to verify a hypothetic inflammatory etiopathogeny of portal hypertension that could be the cause of its evolutive heterogeneity. Male Wistar rats were divided into one control group (n=11) and one group with a triple stenosing ligation of the portal vein ...

BACKGROUND Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on portal hypertension has not yet been investigated. CASE PRESENTATION A 55 year old male patient presented with PPHTN and alcoholic liver cirrhosis. 10 mg of Tadalafil, a PDE5 inhibitor with a long half-life, was ...

The effect of portal arterialization was examined in 20 heterotopic auxiliary rat livers. Portal blood was supplied from recipient iliac artery (0.58 mm in diameter) connected to the donor portal vein using the cuff technique. Portal hypertension caused by arterial blood pressure resulted in the immediate operative death by bleeding in four of the rats (20%) from the spontaneous rupture of the ...

Portal hypertension is one of the most important cause of morbidity and mortality in cirrhotic patients. Over the last decades several randomized controlled trials have led to standard treatment options. As standard of care, the effective therapy for controlling portal hypertension is non-selective beta blockers (NSBBs). These drugs ameliorate portal pressure by lowering splanchnic blood flow a...